Dr. Lipson is a cutaneous oncology and clinical immunotherapy specialist at Johns Hopkins. He received his medical degree in 2005 from the Mount Sinai School of Medicine in New York City, where he graduated with distinction in research. He completed his internship and residency in Internal Medicine at The Johns Hopkins Hospital, and completed a Medical Oncology fellowship at the Johns Hopkins Kimmel Cancer Center.
Dr. Lipson's primary research interest is in early-phase clinical trials for patients with melanoma and other skin cancers. As a member of the Johns Hopkins Melanoma and Cancer Immunology Programs, he focuses on evaluating novel therapies for patients with high-risk or advanced disease. Dr. Lipson is a principal or co-investigator on multiple trials, involving partners from both industry and academia, which focus on the clinical development of antibodies that block the PD-1/PD-L1 pathway. Dr. Lipson’s publications include the first description of successful PD-1 re-induction therapy (Clin Can Res 2013), and the first reports of organ transplant recipients treated with immune checkpoint inhibitors for advanced cancer (JCO 2014, NEJM 2016).
Based on his published work, Dr. Lipson initiated a clinical trial testing a novel combination of immune-based therapies for kidney transplant recipients with advanced selected cancers. This trial is the first of its kind and is being activated at several academic cancer centers across the US.
In addition to his research activities, Dr. Lipson is an internationally-recognized educator in the field of cancer immunotherapy. Many of his lectures focus on the management of immune-mediated drug toxicities associated with novel cancer drugs. Dr. Lipson conducts regular clinical practices in Baltimore, Maryland and at Sibley Memorial Hospital in Washington, D.C. as part of the multidisciplinary Melanoma Program at Johns Hopkins.